Literature DB >> 21607615

p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study.

Ahmet Taner Sümbül1, Hikmet Akkız, Süleyman Bayram, Aynur Bekar, Ersin Akgöllü, Macit Sandıkçı.   

Abstract

The tumor suppressor p53 gene plays a crucial role in preventing carcinogenesis through its ability to induce cell cycle arrest and apoptosis following DNA damage and oncogene activation. A guanine (G)/cytosine (C) common single nucleotide polymorphism (SNP) at second position of codon 72 in exon 4 of p53 gene determines a arginine (Arg) to proline (Pro) (Arg72Pro) aminoacidic substitution within the proline-rich domain of p53 protein. Arg72 and Pro72 allele are different from a biochemical and biological point of view and many reports suggest that they can modulate individual cancer susceptibility. To determine the association of the p53 Arg72Pro polymorphism with the risk of hepatocellular carcinoma (HCC) development in a Turkish population, a hospital-based case-control study was designed consisting of 119 subjects with HCC and 119 cancer-free control subjects matched for age, gender, smoking and alcohol status. The genotype frequency of the p53 Arg72Pro polymorphism was determined by using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Our data shows that the Pro/Pro genotype of the p53 Arg72Pro polymorphism is associated with increased risk of HCC development in this Turkish population (OR = 3.20, 95% CI: 1.24-8.22, P = 0.02). Furthermore, according to stratified analysis, a significant association was observed between the homozygote Pro/Pro genotype and HCC risk in the subgroups of male gender (OR = 3.01, 95% CI: 1.14-7.97, P = 0.03) and patients with hepatitis B virus (HBV)-related HCC (OR = 4.04, 95% CI: 1.46-11.15, P = 0.007). Because our results suggest for the first time that the Pro/Pro homozygote of p53 Arg72Pro polymorphism may be a genetic susceptibility factor for HCC (especially in the male gender and HBV-infected patients) in the Turkish population, further independent studies are required to validate our findings in a larger series, as well as in patients of different ethnic origins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607615     DOI: 10.1007/s11033-011-0903-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  46 in total

Review 1.  Biomarkers in cancer staging, prognosis and treatment selection.

Authors:  Joseph A Ludwig; John N Weinstein
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

Review 2.  Polymorphic variants in the p53 pathway.

Authors:  M E Murphy
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

3.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Molecular basis for heterogeneity of the human p53 protein.

Authors:  N Harris; E Brill; O Shohat; M Prokocimer; D Wolf; N Arai; V Rotter
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

5.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

Review 6.  TP53 and liver carcinogenesis.

Authors:  Frank Staib; S Perwez Hussain; Lorne J Hofseth; Xin W Wang; Curtis C Harris
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

8.  Trp53-dependent DNA-repair is affected by the codon 72 polymorphism.

Authors:  M Siddique; K Sabapathy
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

Review 10.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

View more
  16 in total

1.  Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.

Authors:  Moqin Qiu; Yingchun Liu; Xiangyuan Yu; Linyuan Qin; Chunhua Bei; Xiaoyun Zeng; Xiaoqiang Qiu; Bo Tang; Songqing He; Hongping Yu
Journal:  Tumour Biol       Date:  2015-10-17

2.  Association of p53 codon 72 polymorphism with susceptibility to hepatocellular carcinoma in a Chinese population from northeast Sichuan.

Authors:  Jiajing Cai; Yan Cai; Qiang Ma; Fan Chang; Lei Xu; Guoyuan Zhang; Xiaolan Guo
Journal:  Biomed Rep       Date:  2017-01-11

Review 3.  Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.

Authors:  Mohammad Haroon Khan; Aftab Khalil; Hamid Rashid
Journal:  Genet Res (Camb)       Date:  2015-04-17       Impact factor: 1.588

4.  Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas.

Authors:  Leona N Council; Chandrakumar Shanmugam; Esther A Suswam; Venkat R Katkoori; Martine J Heslin; Alex Hanna; Nirag C Jhala; Sooryanarayana Varambally; Upender Manne
Journal:  J Dig Dis Hepatol       Date:  2016-12-23

5.  p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis.

Authors:  Shuting Jia; Wenru Tang; Ying Luo
Journal:  Hepatol Int       Date:  2012-08-03       Impact factor: 6.047

6.  The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.

Authors:  Surong Hu; Lianying Zhao; Jingting Yang; Miao Hu
Journal:  Tumour Biol       Date:  2013-12-11

7.  HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility.

Authors:  Yuchun Li; Kaijuan Wang; Liping Dai; Peng Wang; Chunhua Song; Jianxiang Shi; Pengfei Ren; Hua Ye; Jianying Zhang
Journal:  Oncol Lett       Date:  2012-05-23       Impact factor: 2.967

8.  Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.

Authors:  Long Lv; Ping Wang; Xiaoqing Zhou; Beicheng Sun
Journal:  Tumour Biol       Date:  2013-04-06

9.  Influence of angiotensin I-converting enzyme gene polymorphism on hepatocellular carcinoma risk in China.

Authors:  Fang Yuan; Lu-Shun Zhang; Hong-Yu Li; Miao Liao; Meili Lv; Chongjie Zhang
Journal:  DNA Cell Biol       Date:  2013-04-09       Impact factor: 3.311

Review 10.  Role of Sex in the Therapeutic Targeting of p53 Circuitry.

Authors:  Francesca Mancini; Ludovica Giorgini; Emanuela Teveroni; Alfredo Pontecorvi; Fabiola Moretti
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.